Curated News
By: NewsRamp Editorial Staff
September 29, 2025
VolitionRx Partners with Hologic to Expand Nu.Q® Discover Service Access
TLDR
- VolitionRx gains market advantage through its co-marketing agreement with Hologic, expanding access to its $200 million annual market Nu.Q Discover assays.
- VolitionRx's agreement with Hologic provides drug developers with epigenetic profiling assays across disease model development, preclinical testing, and clinical studies.
- This partnership advances epigenetic research to help detect diseases earlier, potentially improving patient outcomes and quality of life through better diagnostics.
- VolitionRx collaborates with Hologic to offer nucleosome quantification services, providing novel biological insights across oncology and neurodegenerative diseases.
Impact - Why it Matters
This partnership between VolitionRx and Hologic represents a significant advancement in pharmaco-epigenetics that could accelerate drug development across multiple disease areas. For patients, this collaboration means potentially faster development of new treatments and improved diagnostic tools for conditions ranging from cancer to cardiovascular and neurodegenerative diseases. The expanded access to Nu.Q® Discover assays through Hologic's established network could lead to more efficient clinical trials and better understanding of disease mechanisms, ultimately resulting in earlier detection and more personalized treatment approaches. In the broader healthcare landscape, this agreement demonstrates the growing importance of epigenetic profiling in modern medicine and could set new standards for how pharmaceutical companies approach drug development and disease monitoring.
Summary
VolitionRx Ltd. (NYSE American: VNRX), a multi-national epigenetics company, has announced a significant co-marketing and services agreement with Hologic Diagenode, part of Hologic Inc. (NASDAQ: HOLX), to promote Volition's Nu.Q® Discover service. This strategic partnership represents a major milestone for the Nu.Q® Discover program, which offers drug developers and scientists a comprehensive suite of assays for rapid epigenetic profiling across disease model development, preclinical testing, and clinical studies. The collaboration leverages Hologic's extensive experience in oncology and other disease areas including cardiovascular, neurodegenerative, and immunology, where nucleosome quantification can provide valuable biological insights to biotech, pharma, and academic clients.
Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition, emphasized that this agreement will greatly expand customer access to Volition's proprietary Nu.Q® Discover assays, which target an estimated total addressable market of $200 million annually. The partnership strengthens Volition's position in the pharmaco-epigenetics market and supports revenue growth objectives. Raphael Werding, Head of Life Sciences at Hologic, expressed enthusiasm for adding Nu.Q® Discover to their service offering, highlighting the potential for nucleosome quantification to deliver additional biological insights across multiple disease areas. The initial one-year agreement includes potential expansion into an exclusive provider arrangement, demonstrating the long-term strategic nature of this collaboration.
Volition, with research and development activities centered in Belgium and additional operations in the U.S. and London, remains dedicated to advancing epigenetics science through its focus on early disease detection and monitoring. The company's broader mission involves developing simple, cost-effective blood tests to detect and monitor various diseases, including cancers and conditions associated with NETosis such as sepsis. This partnership with Hologic represents a significant step forward in making advanced epigenetic profiling more accessible to the broader scientific and pharmaceutical communities, potentially accelerating drug development and improving patient outcomes through earlier detection and more effective treatment monitoring.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VolitionRx Partners with Hologic to Expand Nu.Q® Discover Service Access
